CAS: 106308-44-5; 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide

该化合物是一种主要用于治疗伦诺克斯-加斯塔特综合症的抗凝胶药物,是一种严重的癫痫,其特点是化学配方,包括一种独特的结构,能够调节钠管,从而稳定...

结构式图片

欧盟法规

C&L通报

上下游产品

2-(azidomethyl)-1,3-difluorobenzene 2-Chloroacrylonitrile CGP 47292 methyl 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylate

合成工艺路线路线简述

    2-(叠氮甲基)-1,3-二氟苯置于ammonium Hydroxide,三乙胺体系中,用 甲醇,水 用作溶剂,化学反应 66.0H,反应生成卢非酰胺
    参考文献:抗癫痫药1-(2,6-二氟苄基)-1 H-1,2,3-三唑-4-羧酰胺(rufinamide)及其类似物的新无溶剂和无金属合成
    标题:抗癫痫药1-(2,6-二氟苄基)-1 H-1,2,3-三唑-4-羧酰胺(rufinamide)及其类似物的新无溶剂和无金属合成
    摘要:这项工作提出了一种抗癫痫药芦丁酰胺的新合成形式-化学形式的1-(2,6-二氟苄基)-1 H-1,2,3-三唑-4-羧酰胺)和一些类似的化合物,锅式反应采用无溶剂,无金属的催化,不需任何还原剂.提出的一个新奇的东西是从苯甲酸合成新的前体物4-三氯乙酰-1-(2,6-二氟苄基/苄基/ 4-甲氧基苄基)-5-甲基(苯基)-1 H-1,2,3-三唑. 1,1,1-三氯-4-烷氧基烷-3-En-2-Ones和一些苄基叠氮化物之间的区域选择性1,3-偶极环加成反应,通过与水溶液的加成-消除反应转化为芦丁酰胺和类似物nh 4溶液oh的收率很高(42-52%).
    Doi:10.1016/j.Tetlet.2014.11.125

    专利信息


    专利号:US-2023173450-A1
    优先权日:2020-04-28
    标题:Automated chemical synthesis platform
    发明人:CRONIN LEROY; MEHR HESSAM; CRAVEN MATTHEW; LEONOV ARTEM
    权利人:UNIV GLASGOW COURT
    摘要:The invention provides a method for controlling an automated chemistry platform using synthetic procedures written in natural language. The method uses natural language processing (NLP) techniques to interpret a synthetic procedure written in natural scientific language and extracts a machine-readable instruction set comprising the distinct operations necessary for carrying out the synthesis on an automated chemical synthesis platform. The method optionall also includes the step of executing the machine-readable instruction set on an automated chemical synthesis platform.

    专利号:WO-2025017001-A1
    优先权日:2023-07-18
    标题 :Method and device for automation of chemical synthesis
    发明人:CHATTERJEE SOURAV; MOON SOOYEON
    权利人:CHATTERJEE SOURAV; MOON SOOYEON
    摘要:The present disclosure relates to a chemical synthesizer (1) and a method for performing a chemical synthesis on a chemical synthesizer (1), the chemical synthesizer comprising an automated chemical reactor (12), a communication module (13), and a control module (11), the method comprising receiving, in the control module (11) using the communication module (13), a recipe message from a blockchain platform, the recipe message comprising an encrypted chemical synthesis recipe; decrypting, in the control module (11), the encrypted chemical synthesis recipe using a cryptographic key securely stored in the control module (11); and performing, in the automated chemical reactor (12), the chemical synthesis according to the chemical synthesis recipe.

    专利号:RU-2177942-C2
    优先权日:1996-07-11
    标 题:Method of synthesis of 1-substituted 4-cyano-1,2,3-triazoles and 4-cyano-1-(2,6-difluorobenzyl)-1h-1,2,3-triazole

    专利号:US-2023149882-A1
    优先权日:2020-04-17
    标题:Fluid handling device and methods
    发明人:CRONIN LEROY
    权利人:UNIV GLASGOW COURT
    摘要:Provided is a fluid handling device having multiple flow pathways through the device. The device has a fluid directing manifold comprising an array of interconnected multi-directional valves, and a plurality of ports in fluid connection with the array. The device also has a controller to set the position of the multi-directional valves. The manifold is configured to provide at least two independent flow paths between a pair of ports within the manifold. Also provided is a method of using the device, and an automated chemical synthesis platform comprising the device.

    专利号:US-11459325-B2
    优先权日:2018-01-31
    标题:Heterocyclic compound
    发明人:TANAKA YUTA; OHASHI TOMOHIRO; IKEDA ZENICHI; TANAKA YUTA; PÜNNER FLORIAN; YAMAMOTO TAKESHI; KAKEGAWA KEIKO; KIKUCHI FUMIAKI; MORISHITA NAO; KASAHARA TAKAHITO; SETO MASAKI; NAKAMURA MINORU; TAKAMI KAZUAKI; MURAKAMI MASATAKA; DAINI MASAKI; MIKAMI SATOSHI; SASAKI MINORU
    权利人:TAKEDA PHARMACEUTICALS CO
    摘要:The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. n The present invention relates to a compound represented by the formula (I): n nwherein each symbol is as described in the specification, or a salt thereof.

    专利号:CN-107141235-B
    优先权日:2017-06-21
    标 题 :A kind of method and its drug of the lower synthesis benzyl azide of blue light excitation
    北京嘉盛扬医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.chemsun.cn
    企业联系电话:010-63786746,63786429,63787357👤
    📞北京嘉盛扬医药科技有限公司 ⚠️参考联系方式
    联系人:费先生
    电话:010-63786746,63786429,63787357
    手机:13911777236
    传真:010-63787446
    邮箱:market@chemsun.cn
    通信地址: 北京市丰台科技园海鹰路9号2号楼2层
    邮编: 100070
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:北京市丰台科技园海鹰路9号2号楼2层
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    重庆康乐制药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.cqkl.com.cn
    企业联系电话:023-68980207👤
    📞重庆康乐制药有限公司 ⚠️参考联系方式
    联系人:李伟
    电话:023-68980207


    邮箱:cqkl@cqkl.com.cn
    通信地址: 重庆(长寿)化工园区,化中大道4号
    邮编: 400061
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:重庆(长寿)化工园区,化中大道4号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    湖北威德利化学科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.widelychemical.com
    企业联系电话:13385289472👤
    📞湖北威德利化学科技有限公司 ⚠️参考联系方式
    联系人:赵方
    电话:13385289472
    手机:13385289472
    传真:027- 59222918
    邮箱:z13385289472@163.com
    通信地址: 湖北省武汉市硚口区解放大道204号
    邮编: 430033
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:湖北省武汉市硚口区解放大道204号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Cha JH, Choi H, Yim J, Kim KJ, Nam M, Nam MH, Lee CK, Kim DW, Cho Y, Yun SG. Development of a UPLC-MS/MS Method to Simultaneously Measure 13 Antiepileptic Drugs with Deuterated Internal Standards. Clin Lab. 2024 Sep 1;70(9). doi: 10.7754/Clin.Lab.2024.240206. 66(1708):e133-e140. doi: 10.58347/tml.2024.1708b. 66(1708):121-128. doi: 10.58347/tml.2024.1708a. 75(3). doi: 10.26402/jpp.2024.3.01. Epub 2024 Jul 18. 476(10):1445-1473. doi: 10.1007/s00424-024-02980-7. Epub 2024 Jul 5. Erratum in: Pflugers Arch. 2024 Oct;476(10):1623. doi: 10.1007/s00424-024-02995-0.
    7: Zhang H, Ou Z, Zhang E, Liu W, Hao N, Chen Y, Liu Y, Ye H, Zhou D, Wu X. Efficacy and safety of add-on antiseizure medications for focal epilepsy: A network meta-analysis. Epilepsia Open. 2024 Aug;9(4):1550-1564. doi: 10.1002/epi4.12997. Epub 2024 Jun 18.
    8: Porwal MH, Razzak AN, Kumar V, Obeidat AZ, Sharma U. An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database. Epilepsy Res. 2024 Jul;203:107382. doi: 10.1016/j.eplepsyres.2024.107382. Epub 2024 May 17. 46(5):664-671. doi: 10.1097/FTD.0000000000001219. Epub 2024 May 15.

    合成参考文献


    参考文献:10.2165/11530220-000000000-00000
    摘要:Michoulas A, Farrell K. Medical management of Lennox-Gastaut syndrome. CNS Drugs. 2010 May;24(5):363–74. doi: 10.2165/11530220-000000000-00000.
    参考文献:10.1107/s1600536811006684
    摘要:Dong SL, Cheng XC. Methyl 1-(2,6-difluoro-benz-yl)-1H-1,2,3-triazole-4-carboxyl-ate. Acta Crystallogr Sect E Struct Rep Online. 2011 Apr 01;67(Pt 4):o769.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知